Key points from article :
1E Therapeutics, a new biotech startup in Israel, has raised $120 million in seed funding, marking the largest investment of its kind for an Israeli biotech. Founded just five months ago, the company focuses on developing RNA-targeting therapeutics with a proprietary drug design platform aimed at chronic diseases and emerging pathogens. This funding supports 1E's work on compounds targeting complex health conditions, including cancer, age-related diseases, immunology issues, antimicrobial resistance, viral infections, and rare neurological disorders.
Located in Israel’s Rehovot Science Park, 1E’s facility houses advanced equipment valued at tens of millions, showcasing a commitment to cutting-edge research and innovation. The lab setup and resources are noted to be on par with much larger, established firms. The team at 1E is growing quickly, with dozens of researchers attracted to the company’s groundbreaking work and high-tech environment.
The company’s leadership draws from a deep background in synthetic biology, biomimetics, and therapeutic technology. This expertise strengthens 1E’s approach to developing novel treatments for critical health issues. The company’s proprietary platform enables it to create therapeutics that address a wide range of medical needs in a timely and efficient way.
One of Israel’s top investors, known for involvement in biotech, cyber security, and AI sectors, is a major backer of the company. He has previously collaborated with the scientific leadership of 1E in related biotech ventures, contributing extensive experience in both life sciences and high-tech industries. This considerable investment underscores strong confidence in 1E Therapeutics’ potential to deliver transformative treatments for pressing health challenges, fueling its ambitious journey to develop solutions for complex diseases.
